Scholarlink

Background <p>Traditional management strategies for Idiopathic intracranial hypertension (IIH) frequently demonstrate variable effectiveness, variable patient tolerance, and high rates of clinical recurrence. This systematic review sought to consolidate the available evidence regarding the effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists in adult IIH patients.</p> Methods <p>Relevant studies were identified via a systematic search of various databases, up to July 2025. Trials and observational cohorts were selected if they had assessed GLP-1 receptor agonists in adult subjects with idiopathic intracranial hypertension. Data were abstracted independently by two assessors, and risk of bias was evaluated with the ROBINS-I or RoB 2 tools. Meta-analyses were executed in the Review Manager (RevMan 5.4) software, employing a random-effects approach in order to accommodate heterogeneity across trials.</p> Results <p>Eight studies involving 18,423 patients with idiopathic intracranial hypertension were included in this meta-analysis. Treatment with GLP-1 receptor agonists significantly improved headache outcomes at 6&#xa0;months (RR = 0.77) and reduced papilledema resolution risk at 3&#xa0;months (RR = 0.39). The risk of refractory IIH was lowered across all time points, with a 24-month RR of 0.81. Visual disturbances were also significantly reduced (3-month RR = 0.35), and BMI decreased notably at 6&#xa0;months (MD = − 0.81&#xa0;kg/m<sup>2</sup>).</p> Conclusion <p>GLP-1 receptor agonists yield marked clinical improvements in idiopathic intracranial hypertension, evidenced by a reduced risk of an ICD-coded headache diagnosis during follow-up, decreased papilledema severity, resolution of visual symptoms, and notable reductions in body mass index. Collectively, these results endorse their viability as promising supplementary agents in conjunction with conventional therapeutic paradigms for IIH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Ahmed Farid Gadelmawla,
  • Abdelrahma M. Elettreby,
  • Reema Aldawsari,
  • Abdulelah Asiri,
  • Basel Almutairi,
  • Ruba Al Murayyi,
  • Abdulaziz Alsuhaibani,
  • Lujain Suhaqi,
  • Shouq Aloufi,
  • Shatha Althobaiti,
  • Norah Alhweish,
  • Roaa Al Murayyi,
  • Abdulaziz Altamimi,
  • Ibraheem Altamimi,
  • Mansuor A. Alanazi

摘要

Background

Traditional management strategies for Idiopathic intracranial hypertension (IIH) frequently demonstrate variable effectiveness, variable patient tolerance, and high rates of clinical recurrence. This systematic review sought to consolidate the available evidence regarding the effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists in adult IIH patients.

Methods

Relevant studies were identified via a systematic search of various databases, up to July 2025. Trials and observational cohorts were selected if they had assessed GLP-1 receptor agonists in adult subjects with idiopathic intracranial hypertension. Data were abstracted independently by two assessors, and risk of bias was evaluated with the ROBINS-I or RoB 2 tools. Meta-analyses were executed in the Review Manager (RevMan 5.4) software, employing a random-effects approach in order to accommodate heterogeneity across trials.

Results

Eight studies involving 18,423 patients with idiopathic intracranial hypertension were included in this meta-analysis. Treatment with GLP-1 receptor agonists significantly improved headache outcomes at 6 months (RR = 0.77) and reduced papilledema resolution risk at 3 months (RR = 0.39). The risk of refractory IIH was lowered across all time points, with a 24-month RR of 0.81. Visual disturbances were also significantly reduced (3-month RR = 0.35), and BMI decreased notably at 6 months (MD = − 0.81 kg/m2).

Conclusion

GLP-1 receptor agonists yield marked clinical improvements in idiopathic intracranial hypertension, evidenced by a reduced risk of an ICD-coded headache diagnosis during follow-up, decreased papilledema severity, resolution of visual symptoms, and notable reductions in body mass index. Collectively, these results endorse their viability as promising supplementary agents in conjunction with conventional therapeutic paradigms for IIH.